Summary
Overview
Work History
Education
Skills
Publications In Preparation
Certification And Training
Publications
Conference Abstracts
Timeline
Generic
MOHAMMAD ATIQUR RAHMAN

MOHAMMAD ATIQUR RAHMAN

Ph.D. Candidate
Houston,TX

Summary

Self-motivated Scientist and Ph.D. candidate in Pharmacology with 11+ years of combined research and practical experience. I am a Ph.D. candidate in Pharmacology with 11+ years of research experience in cell and molecular biology, translational science, clinical pharmacology, and pharmacometrics. My expertise includes in vitro and in vivo experimental design, PK/PD and PBPK modeling, and quantitative systems pharmacology (QSP). I have hands-on experience with Phoenix NLME, GastroPlus, Simcyp, and R/Matlab-based modeling tools to integrate computational approaches into drug development. With strong analytical, communication, and collaborative skills, I am committed to advancing precision medicine through model-informed drug development and translational research.

Overview

14
14
years of professional experience
2026
2026
years of post-secondary education

Work History

Cardiovascular Research

University of Houston
08.2020 - Current
  • Demonstrated expertise in mastering and adapting a variety of molecular and biochemical techniques to enhance cell-based assays, including mammalian cell culture, DNA sequencing, PCR, western blotting, ELISA, cell transfection, immunohistochemistry, histology, protein purification, molecular cloning, flow cytometry, and confocal microscopy
  • Investigated the molecular mechanisms of nicotine-induced glomerular damage, identifying two critical pathways and proposing therapeutic options validated through in-vivo and in-vitro models
  • Executed nephrectomy procedures with precision, showcasing proficiency in anesthetic administration, surgical intervention, and post-operative care to optimize recovery outcomes
  • Developed a physiologically based pharmacokinetic (PBPK) model for Amitriptyline using GastroPlus and PK-Sim to predict systemic and kidney-specific drug distribution, incorporating absorption, metabolism, and renal clearance parameters
  • Authored manuscripts by conducting data analysis, statistical processing, and figure generation, while maintaining meticulous laboratory records for accurate reporting
  • Communicated research findings effectively through poster and oral presentations at conferences and seminars

Behavioral Neuroscience Research

Rowan University
08.2018 - 05.2020
  • Managed and executed research on the behavioral and pharmacological aspects of the novel molecule μ-opioid analgesic IBNtxA, assessing its potential abuse liability and discriminative stimulus effects
  • Led a significant project that uncovered important interactions between α2GABAA, α3GABAA, and μ-opioid receptor-mediated signals, highlighting the potential of combination therapy for treating pain-related disorders
  • My research findings established a strong foundation and were fundamental in securing approximately $2M in NIH grant funding, reflecting my commitment to advancing innovative and impactful research in the field of pharmacotherapy

Product Management Specialist

Globe Pharmaceuticals Ltd.
02.2013 - 07.2017
  • Led the development and optimization of pharmaceutical products, applying scientific principles to ensure quality, safety, and efficacy throughout the product lifecycle
  • Analyzed pharmacological data and performed preclinical research to support the development and innovation of new pharmaceutical products

Student Internship

Healthcare Pharmaceuticals Ltd.
05.2011 - 08.2011
  • Successfully managed inventory, contributed to product development, and optimized manufacturing processes, ensuring quality control, regulatory compliance, and enhanced production efficiency in a pharmaceutical setting

Education

Ph.D. - Pharmacology

University of Houston
Houston, TX
07-2025

M.Sc. - Pharmaceutical Science

Rowan University
Glassboro, NJ

Bachelor of Pharmacy (Hon’s) - undefined

Stamford University Bangladesh
Dhaka, Bangladesh

Skills

Pharmacokinetic Analysis

Publications In Preparation

  • Membrane raft redox signaling pathway mediates gut microbial metabolite TMAO-induced NLRP3 inflammasome activation and cardiovascular dysfunction.
  • Membrane raft redox signaling pathway in nicotine-Induced NLRP3 inflammasome activation and renal injury.
  • Effects of Membrane Raft Redox Signaling in Gut Microbial Metabolite TMAO-Induced NLRP3 Inflammasome Activation and Podocyte Injury.

Certification And Training

  • University of Florida, Orlando, FL, 01/25, Florida Winter School on Modeling and Simulation in PK/PD, Managed Conducted guided PBPK model development and verification using PK-Sim., Modeled drug-drug interactions and mechanism-based inhibition., Applied PBPK concepts to simulate drug behavior in special populations., Developed PBPK models for IV and oral administration.
  • Certara University, 06/24-12/24, Pharmacokinetic Data Analysis, Expert in using Phoenix WinNonlin and Phoenix NLME for Non-compartmental Analysis (NCA)., Skilled in using GastroPlus for PBPK modeling.
  • NIH, Principles of Clinical Pharmacology, Principles and Practice of Clinical Research, Gaining deep expertise in drug development and clinical trial methodologies.

Publications

  • Acid sphingomyelinase and ceramide signaling pathway mediates nicotine-induced NLRP3 inflammasome activation and podocyte injury., Rahman, M. A., Datta, S., Lakkakula, H., Koka, S., Boini, K. M., Biomedicines, 2025, 13, 416, https://doi.org/10.3390/biomedicines13020416
  • High mobility group box 1 (HMGB1) mediates nicotine-induced podocyte injury., Datta, S., Rahman, M. A., Koka, S., & Boini, K. M., Frontiers in pharmacology, 2025, 15, 1540639, https://doi.org/10.3389/fphar.2024.1540639
  • High Mobility Group Box 1 (HMGB1): Molecular Signaling and Potential Therapeutic Strategies., Datta, S., Rahman, M. A., Koka, S., & Boini, K. M., Cells, 2024, 13, 23, 1946, https://doi.org/10.3390/cells13231946
  • Synergistic antihyperalgesic and antinociceptive effects of morphine and methyl 8-ethynyl-6-(pyridin-2-yl)-4H-benzo[f]imidazo[1,5-a][1,4]diazepine-3-carboxylate (MP-III-024): a positive allosteric modulator at α2GABAA and α3GABAA receptors., Rahman, M. A., Keck, T. M., Poe, M. M., Sharmin, D., Cook, J. M., & Fischer, B. D., Psychopharmacology, 2021, 10.1007/s00213-021-05791-1
  • Abuse Liability, Anti-Nociceptive, and Discriminative Stimulus Properties of IBNtxA., Islam, A., Rahman, M. A., Brenner, M. B., Moore, A., Kellmyer, A., Buechler, H. M., DiGiorgio, F., Verchio, V. R., McCracken, L., Sumi, M., Hartley, R., Lizza, J. R., Moura-Letts, G., Fischer, B. D., & Keck, T. M., ACS pharmacology & translational science, 2020, 3, 5, 907–920

Conference Abstracts

  • Membrane raft redox signaling pathway mediates gut microbial metabolite TMAO-induced NLRP3 inflammasome activation and cardiovascular dysfunction., Rahman, Mohammad A., Datta, Sayantap., Koka, Saisudha., Boini, Krishna M., American Association of Pharmaceutical Scientists meeting, 2024, Salt Lake City, UT
  • Membrane raft redox signaling pathway in nicotine-Induced NLRP3 inflammasome activation and renal injury., Rahman, Mohammad A., Datta, Sayantap., Koka, Saisudha., Boini, Krishna M., Journal of Pharmacology and Experimental Therapeutics, 06/24, 389, S3, 462, https://doi.org/10.1124/jpet.462.906960
  • Role of acid sphingomyelinase in nicotine-induced podocyte injury., Rahman, Atiqur., Koka, Saisudha., Boini, Krishna M., Journal of Pharmacology and Experimental Therapeutics, 06/23, 385, S3, 101, https://doi.org/10.1124/jpet.122.286380

Timeline

Cardiovascular Research

University of Houston
08.2020 - Current

Behavioral Neuroscience Research

Rowan University
08.2018 - 05.2020

Product Management Specialist

Globe Pharmaceuticals Ltd.
02.2013 - 07.2017

Student Internship

Healthcare Pharmaceuticals Ltd.
05.2011 - 08.2011

M.Sc. - Pharmaceutical Science

Rowan University

Bachelor of Pharmacy (Hon’s) - undefined

Stamford University Bangladesh

Ph.D. - Pharmacology

University of Houston
MOHAMMAD ATIQUR RAHMANPh.D. Candidate